The burden of Idiopathic Pulmonary Fibrosis (IPF): a multimodal study of prevalence, healthcare utilization and survival

W. Chia (Kirkcaldy, United Kingdom), F. Harrison (Kirkcaldy, United Kingdom), T. Hartley (Kirkcaldy, United Kingdom), D. Szapiro (Kirkcaldy, United Kingdom), D. Dhasmana (Kirkcaldy, United Kingdom)

Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Session: Clinical aspects of idiopathic pulmonary fibrosis
Session type: E-poster session
Number: 767
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Chia (Kirkcaldy, United Kingdom), F. Harrison (Kirkcaldy, United Kingdom), T. Hartley (Kirkcaldy, United Kingdom), D. Szapiro (Kirkcaldy, United Kingdom), D. Dhasmana (Kirkcaldy, United Kingdom). The burden of Idiopathic Pulmonary Fibrosis (IPF): a multimodal study of prevalence, healthcare utilization and survival. 767

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Incidence and prevalence of IPF in an insurance claims database: Assessing accuracy using medical records
Source: International Congress 2014 – Respiratory disease within hospital-based populations
Year: 2014


The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016


The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


The lived experience of idiopatic pulmonary fibrosis: A qualitative study
Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences
Year: 2016


Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016


Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015



Do physicians in primary health care recognize pulmonary fibrosis?
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Predicting life expectancy for pirfenidone and best supportive care (BSC) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016

The efficacy of a walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis (IPF). A pilot study
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015

Review of care in patients dying of pulmonary fibrosis in a district general hospital
Source: International Congress 2016 – Orphan diseases I
Year: 2016


Incidence of idiopathic pulmonary fibrosis in Italy. Analysis of hospital admission and mortality databases of a large Italian region
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013

Incidence and resource utilisation of pulmonary exacerbations in patients with cystic fibrosis in the UK
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010

Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020


The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016

Health status & impact of living with idiopathic pulmonary fibrosis (IPF): UK & Ireland Delphi survey
Source: International Congress 2016 – IPF clinical
Year: 2016



IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015


Quality of life of patients with idiopathic pulmonary fibrosis (IPF) - What can the Australian IPF registry tell us?
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015



Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013